首页 > 市场调查报告书 > 医疗设备

眼科设备手术用器具

市场调查报告书

商品编码

1345394

全球圆锥角膜治疗市场 - 2023-2030

Global Keratoconus Treatment Market - 2023-2030

出版日期: 2023年09月06日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

2022年，全球圆锥角膜治疗市场达到5亿美元，预计到2030年将达到6亿美元，预测期内（2023-2030年）复合年增长率为3.9%。

圆锥角膜是一种视力疾病，当通常为圆形的角膜变薄且不均匀（圆锥形）时，会导致穿透眼睛的光线无法准确地集中在视网膜上并导致视力扭曲。通常，圆锥角膜出现在双眼中并影响中央角膜，圆锥顶位于视轴下方。每 100,000 人中大约有 50 至 200 人患有圆锥角膜。

眼睛相关问题的案例不断增加，研究倡议不断增加，合作、产品批准等市场发展；研究活动和技术进步等因素预计将推动预测期内全球圆锥角膜治疗市场的增长。

动力学

不断增长的市场发展推动了圆锥角膜治疗市场的增长。

市场的不断发展预计将推动预测期内全球圆锥角膜治疗市场的增长。例如，2022 年8 月，Glaukos、眼科医疗技术和製药公司专注于治疗角膜疾病、青光眼和视网膜疾病的新疗法，与iVeena Delivery Systems 签订了战略许可合同，iVeena Delivery Systems 是一家私人持有的临床阶段药物。眼科公司设计非手术、非侵入性药理创新，使 Glaukos 获得全球唯一同意设计和商业化用于圆锥角膜治疗的 IVMED-80。

此外，2023年7月，眼保健品公司博士伦以1.065亿美元的决定价格从强生公司子公司Johnson & Johnson Vision收购了Blink非处方（OTC）滴眼液系列。此次最新收购进一步坚定了该公司坚持通过 OTC 眼部护理开发来提高客户舒适度的决心。

支持圆锥角膜治疗的倡议不断增加，预计将为全球圆锥角膜治疗市场带来增长机会。

支持圆锥角膜治疗的倡议不断增加，预计将为全球圆锥角膜治疗市场在未来几年带来潜在的增长机会。例如，全球圆锥角膜教育计划为您提供在实践中治疗圆锥角膜所需的一切信息，包括圆锥角膜电子资源- 现代圆锥角膜管理的综合指南、关于在临床实践中识别和管理圆锥角膜的网络研讨会。

预计缺乏认识将在预测期内阻碍全球圆锥角膜治疗市场。

缺乏认识预计将阻碍全球圆锥角膜治疗市场的增长。例如，许多与眼睛有关的问题是逐渐发生的，并且是由于疏忽而引起的。其中一些问题是最小的，而另一些则需要昂贵的某些治疗方法。在彻底发展的地区，相当多的人没有足够的钱来选择治疗这些疾病。同样，他们中的大多数人对这些条件缺乏足够的了解，这进一步加剧了严酷性。

有关此报告的更多详细信息 - 索取样品

Overview

The global Keratoconus Treatment market reached US$ 0.5 billion in 2022 and is expected to reach US$ 0.6 billion by 2030, exhibiting a CAGR of 3.9% during the forecast period (2023-2030).

Keratoconus is an eyesight condition that transpires when the commonly round cornea becomes thin and uneven (cone) shaped, preventing the light penetrating the eye from being concentrated accurately on the retina and causing contortion of vision. Usually, keratoconus appears in both eyes and affects the central cornea with the peak of the cone just under the visual axis. Roughly 50 to 200 of every 100,000 individuals are afflicted with keratoconus.

The growing cases of eye-related problems, increasing research initiatives, market developments such as collaborations, product approvals, and other; research activities, and technological advancements among other factors are expected to boost the global Keratoconus Treatment market growth in the forecast period.

Dynamics

Increasing Market Developments Drive the Growth of the Keratoconus Treatment Market.

Increasing market developments are expected to boost the global keratoconus treatment market growth in the forecast period. For instance, in August 2022, Glaukos, ophthalmic medical technology, and pharmaceutical corporation that concentrated on novel treatments for the therapy of corneal disorders, glaucoma, and retinal disorders constituted a strategic licensing contract with iVeena Delivery Systems, a privately held, clinical-stage ophthalmology corporation designing non-surgical, non-invasive, pharmacologic innovations giving Glaukos a sole global consent to design and commercialize IVMED-80 for the therapy of keratoconus.

Moreover, in July 2023, Bausch + Lomb, an eye health products corporation acquired the Blink over-the-counter (OTC) line of eye drops from Johnson & Johnson Vision, a subsidiary of Johnson & Johnson for the decided cost of USD 106.5 million. This most current acquisition adds to the corporation's affirmation to persist in increasing customer comfort with OTC eye care developments.

The Increasing initiatives to support the keratoconus treatment are Expected to Present the Global Keratoconus Treatment Market With Growth Opportunities.

The increasing initiatives to support the keratoconus treatment are expected to present the global keratoconus treatment market with prospective growth opportunities in the forthcoming years. For instance, the global Keratoconus Education Initiative provides you with everything you need to know to treat keratoconus in your practice including, the Keratoconus eResource- a comprehensive guide to the modern Management of Keratoconus, webinar on identifying and managing keratoconus in clinical practice.

The Lack of Awareness is Estimated to Hamper the Global Keratoconus Treatment Market During the Forecast Period.

The lack of awareness is estimated expected to hamper the global keratoconus treatment market growth. For instance, numerous eye-related issues grow very gradually and are induced because of negligence. Some of these concerns are tiniest, while some require certain therapies that are costly. In thoroughly evolving regions, a considerable number of individuals do not have sufficient money to opt for therapy for these conditions. Again, a majority of them have an insufficient understanding regarding such conditions that, additionally advance the harshness.

For more details on this report - Request for Sample

Segment Analysis

The global keratoconus treatment market is segmented based on type, treatment type, end-users, and region.

The Surgical Treatment Type Segment of Keratoconus Treatment is Estimated to Dominate the Global Keratoconus Treatment Market.

The surgical treatment type segment of the keratoconus treatment is expected to hold around 27.8% of the global market share owing to the increasing research activities. For instance, in January 2023, Glaukos, ophthalmic medical technology, and pharmaceutical corporation that concentrated on novel treatments for the therapy of corneal disorders, glaucoma, and retinal disorders declared the positive outcomes for a forthcoming, multi-center clinical investigation devised to assess the safeness of the surgical exchange approach for travoprost intraocular implant in individuals who had already obtained a travoprost intraocular implant in the Phase 2b clinical trial, also called the exchange trial.

Furthermore, the increasing initiatives in the surgical treatment type also contribute to segment growth. For instance, in April 2023, Michael W. Belin, MD, CMO of CXL Ophthalmics, Inc., a clinical-stage corporation designing a minimally invasive keratoconus therapy, is expected to provide the Plenary Session at the first International Keratoconus Academy (IKA) Symposium. The meeting is expected to get joint optometrists, ophthalmologists, and industry professionals curious about the administration and therapy of keratoconus.

Ggeographical Penetration

North America is estimated to hold Approximately 38.3% of the Market Share by 2030, Owing to Market Developments in this Region.

Owing to the increasing market developments in the North American region, it is estimated to dominate the global market holding around 38.3% of the market by 2030. For instance, For instance, in November 2022, CooperVision added SynergEyes to its CooperVision professional eye care industry segment, intensifying its promise to promote the usage of professional contact lenses in North America and almost the globe. The mixed lens approaches and trademarks presented by the Carlsbad, California-based corporation cover the therapy of uneven cornea, presbyopia, and astigmatism.

Furthermore, the increasing research activities on keratoconus also contribute to the regional market growth in the forecast period. For instance, the investigators at the North Texas Eye Research Institute recognized, separated, and characterized tear EVs (tEVs) in keratoconus patients and discovered that they have a different phenotype corresponding to their healthy counterparts. In the investigation, 10 healthy subjects and nine keratoconus-diagnosed individuals were analyzed. Men with eye disorders were also discovered to have more elevated total counts of tEVs than females.

Competitive Landscape

The major global players in the keratoconus treatment market include: Sandoz International GmbH, HOYA, Menicon Co., Ltd., The Cooper Companies, Inc., Bausch Health Companies Inc., SynergEyes, Carl Zeiss Meditec AG, Contamac, SEED Co., Ltd, Novartis AG, and Johnson & Johnson Services, Inc., among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is assumed to have had a moderate impact on the global keratoconus treatment market, as during the 3 months of full-scale warfare, Russians sabotaged over 600 infirmaries and massacred at least 12 medics. Access to health care is majorly affected because of security considerations, limited mobility, damaged supply chains, and mass population eviction. Also, the lack of primary market players in this region. In addition to it, the significance of the import and export of fundamental materials are expected to slightly impact the global Keratoconus Treatment market growth in the forecast period.

By Type

Corneal Hydrops
Forme Fruste Keratoconus
Posterior Keratoconus
Keratoglobus
Pellucid Marginal Degeneration

By Treatment Type

Lenses
Therapies
Surgery
Others

By End-Users

Hospitals
Homecare
Specialty Clinics
Others

By Region

North America
- U.S.
- Canada
- Mexico

Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe

South America
- Brazil
- Argentina
- Rest of South America

Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific

Middle East and Africa

Key Developments

In May 2023, Menicon Co., Ltd. declared that Itabashi Medical (Dalian) Co., Ltd., a Chinese affiliate, launched "ROSE K" in China in April 2023. A hard contact lens for keratoconus individuals is called ROSE K.
In September 2022, CXL Ophthalmics, Inc., a clinical-stage corporation designing a minimally-invasive treatment for keratoconus, declared positive outcomes of the EpiSmart cross-linking Phase 2 study for keratoconus in Cornea.
In September 2022, CXL Ophthalmics, Inc., a clinical-stage corporation designing a minimally-invasive treatment for keratoconus, secured a $32 million Series A funding round led by AXA IM Alts through its Global Health Private Equity approach plus a syndicate of individual investors, including leading cornea specialists.

Why Purchase the Report?

To visualize the global keratoconus treatment market segmentation based on type, treatment type, end-users, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous keratoconus treatment market-level data points with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available in excel consisting of key products of all the major players.

The global keratoconus treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Treatment Type
3.3. Snippet by End-Users
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Market Developments
  - 4.1.1.2. Research Advancements
- 4.1.2. Restraints
  - 4.1.2.1. Lack of Awareness
- 4.1.3. Opportunity
  - 4.1.3.1. Increasing Initiatives
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. By Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
7.2. Corneal Hydrops*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Forme Fruste Keratoconus
7.4. Posterior Keratoconus
7.5. Keratoglobus
7.6. Pellucid Marginal Degeneration

8. By Treatment Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 8.1.2. Market Attractiveness Index, By Treatment Type
8.2. Lenses*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Therapies
8.4. Surgery
8.5. Others

9. By End-Users

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
- 9.1.2. Market Attractiveness Index, By End-Users
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Homecare
9.4. Specialty Clinics
9.5. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. The U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. The U.K.
  - 10.3.6.3. France
  - 10.3.6.4. Spain
  - 10.3.6.5. Italy
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan

Australia

10.5.6.4. Rest of Asia-Pacific

10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Sandoz International GmbH*
- 12.1.1. Company Overview
- 12.1.2. Type Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. HOYA
12.3. Menicon Co., Ltd.
12.4. The Cooper Companies, Inc.
12.5. Bausch Health Companies Inc.
12.6. SynergEyes
12.7. Carl Zeiss Meditec AG
12.8. Contamac
12.9. SEED Co., Ltd
12.10. Novartis AG
12.11. Johnson & Johnson Services, Inc.

LIST NOT EXHAUSTIVE

13. Appendix

13.1. About Us and Types
13.2. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格